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Objectives: The existing guidelines recommend the minimum effective dose of 
inhaled corticosteroids in children with persistent asthma. Clinical studies and 
recent Cochrane reviews stablish the existence of a significant difference in the 
growth rate of pediatric patients that receive corticoids against those who do not 
receive them1-5. Another study showed that pediatric patients treated with sub-
cutaneous immunotherapy (IT) to house dust mites required a significant lower 
dose of fluticasone propionate (PF). Quantify the savings associated with the dose 
decrease of PF in pediatric patients with allergic asthma treated for three years 
with high dose specific-allergen immunotherapy to mites MethOds: The average 
reduction of PF comes from an observational, randomized, three years prospective 
study (N= 65; 33 treated with IT+FP). The number of containers per patient were 
calculated as well as its economical savings regarding the baseline situation. The 
immunotherapy used and the PF were accounted for by means of RRP. Results: 
The PF accumulated savings is equivalent to 29,3% of the immunotherapy phar-
macological costs. Since PF is a reduced contribution medication, the savings for 
the NHS are 44,9%-67,3% and 5,9%-3,9% for the patient depending on the income 
range. cOnclusiOns: Adding high dose specific-allergen immunotherapy to mites 
to pharmacological treatment retains control over the allergic asthma and reduces 
the use of corticoids, consequently minimizing the impact on the growth rate of 
the patients and generates economical savings.
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Objectives: To calculate the fluctuation in the drug cost involved in the treatment 
of Chronic Obstructive Pulmonary Disease (COPD) during 2013-2015. MethOds: 
Standard treatment guidelines (STG), 4th edition were perused to understand the 
management of COPD. Current Index of Medical Specialities (CIMS) Oct - Jan 2013, 
2014 and 2015 issue were used to capture the price of drugs. One day cost of treat-
ment and its variation was studied. Results: According to STG, drugs needed 
for the maintenance treatment of COPD includes Salbutamol inhaler 200mcg 4 
times a day or Terbutaline 250mcg inhaler, Ipratropium bromide 200mcg inhaler 
2 times a day, Theophylline 100mg tablets 3 times a day, Amoxicillin + Clavulanic 
acid (500mg + 125mg) injection 3 times a day, Fluticasone 100mcg inhalation once 
a day, Montelukast tablet 5mg once a day. The minimum and maximum difference 
in cost of one day maintenance was found to be 136%, 182% and 169% in the year 
2013, 2014 and 2015 respectively. This fluctuation was observed by totaling the price 
of all the drugs mentioned above. cOnclusiOns: Wide variation exists between 
the minimum and maximum cost of maintainance therapy of COPD. Government 
should take some step in order to regulate and to bring uniformity in price. So that it 
can be affordable by a common man which will ultimately improve the compliance 
and reduce the economic burden.
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Objectives: To analyze the clinical symptoms, treatment pattern, outcomes and 
factors associated with total cost of treatment. MethOds: A retrospective cross 
sectional study was conducted in tertiary care hospital. The patient details such as 
demographical data, clinical features, treatment and outcome were collected from 
the Medical Records Department. The total cost of treatment was collected from 
Finance Department. Data were analyzed by using SPSS 20.0 Results: Mean age of 
the study population was found to be 42.7±18.2 year with majority of male 94(52.2%). 
Sepsis (59(32.8%)) was the most common etiology for ARDS in our study population. 
Analysis of 180 cases showed that total number of hospitalization days were 1793 
and total cost of treatment was 11,005,448 INR. The patients who received corticos-
teroid therapy before 48 hours had better recovery rate. Mean ventilation days in the 
group of patients who received early glucocorticoid therapy were less (9.29±6.06) 
then those who received late therapy (13.64±6.03) cOnclusiOns: Mortality rate 
associated with ARDS was relatively high. Management with steroids has no special 
benefit in reduction in mortality rate. Time of start of steroid therapy plays an impor-
tant role in the management and was observed that early start of steroid therapy 
showed better recovery rate as well as reduction in hospitalization and ventilation 
days. The total treatment cost for the management of ARDS is relatively high.
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Objectives: Retrospective database studies of PAH using US payer claims data 
have limitations due to lack of specific ICD-9 codes for PAH and ability to identify 
patient severity. A previous study validated an algorithm including patients with 
non-specific PH codes and a claim for an advanced PAH drug therapy. This study used 
provider-reported disease severity – FC – to examine the impact of FC on healthcare 
Objectives: Knowing the burden of community-acquired pneumonia (CAP) 
is important for taking preventive measures. This study aimed to calculate 
the direct costs of CAP in adults > 18 years old. MethOds: Data of outpatients 
and inpatients with CAP from 18-month period were retrospectively evaluated. 
Numbers of radiological and laboratory analyses, hospital stay (day), and spe-
cialist visits were multiplied by the relevant unit costs and the cost per patient 
was calculated. Total drug costs were calculated by multiplying daily drug cost 
with medication day for each drug for inpatients and by based on packet price 
of each drug for outpatients. Costs were expressed as median (minimum-max-
imum). Results: The mean ages were 61.56±17.87 years in inpatients (n= 208, 
51.4% males) and, 53.78±17.46 years in outpatients (n= 211, 53.6% males). The 
ratios of being ≥ 65 years old in inpatients and outpatients were 48.6% and 28.9%, 
respectively. Among inpatients, 36.5% had chronic obstructive pulmonary disease 
(COPD) and18.3% had hypertension. Among outpatients, 22.7% had COPD and 
20.4% had asthma. The total cost was 300.01€ (75.11€ -9,870.16€ ) for inpatients 
and 39.43€ (5.34€ -230.34€ ) for outpatients. Drug cost had the highest share of 
total cost both in inpatients and outpatients. In inpatients, total cost was 345.21€ 
(75.11€ -9,870.16€ ) in those ≥ 65 years old and 283.35€ (79.13€ -3,785.71€ ) in those 
< 65 years old (p= 0.014); this difference was not found in outpatients. The total 
cost was 633.73€ (313.11€ -4,375.23€ ) in inpatients hospitalized more than once and 
270.67€ (75.11€ -9,870.16€ ) in those hospitalized once (p< 0.001). In inpatients with 
and without comorbidities, total costs were 308.14€ (75.11€ -9,870.16€ ) and 221.08€ 
(92.20€ -3785.71€ ), respectively (p= 0.016). In outpatients with and without comor-
bidities, total costs were 44.97€ (5.34€ -230.34€ ) and 26.56€ (5.34€ -110.96€ ), respec-
tively (p< 0.001). cOnclusiOns: Costs were higher in patients with advanced 
age, having comorbidity, and hospitalized more than once. For decreasing the 
economic burden of CAP on healthcare system, preventive measures should be 
taken.
PRS25
thE aSSoCiation BEtWEEn Smoking CESSation oUtPatiEnt viSitS and 
total mEdiCal CoStS: an analySiS of JaPanESE EmPloyEE BaSEd PUBliC 
hEalth inSURanCE data
Suwa K1, Nakamura Y2, Yoshikawa R1, Gunji T2, Iwasaki K2, Igarashi A3
1Pfizer Japan Inc., Tokyo, Japan, 2Milliman, Tokyo, Japan, 3University of Tokyo, Graduate School of 
Pharmaceutical Sciences, Tokyo, Japan
Objectives: The purpose of this study was to estimate short-term medical cost 
savings, including costs not directly associated with Smoking Cessation Outpatient 
Visits (SCOVs), from claims data of employee based public health insurance in 
Japan. MethOds: We conducted two analyses using claims data from January 
2005 to December 2013 provided by Japan Medical Data Center Co., Ltd. In the 
first analysis, we compared medical costs composed of inpatient, outpatient, and 
medications of the SCOV group, smokers having SCOVs, with those of non-SCOV 
group for each year. The first day of index year 0 is the day of first SCOV for the 
SCOV group and is the day after one observation year for the non-SCOV group. 
In the second analysis, among smokers with SCOVs, a mean increase ratio of 
medical costs was calculated, varying by the number of SCOVs. Results: In the 
first analysis, medical costs per patient per years (PPPYs) of the SCOV group were 
¥95,200 at year -1, ¥173,400 at year 0, ¥130,900 at year 1 and ¥116,100 at year 5, and 
PPPYs of non-SCOV group were ¥95,200 at year -1, ¥100,700 at year 0, ¥108,100 at 
year 1 and ¥125,900 at year 5. The PPPY of SCOV group at year 0 was higher than 
that of non-SCOV group at year 0 but the relation was reversed at year 5. In the 
second analysis, the mean increase ratio of medical costs of the one-SCOV group 
was the highest, 58%, and that of five-SCOV group was the smallest, 34%. This 
measure showed a downward trend. cOnclusiOns: Results are suggestive of 
a possibility that the future medical costs of patients with smoking cessation 
outpatient visits are lower than those without smoking cessation outpatient visit 
and increasing the number of smoking cessation outpatient visits decreases the 
mean increase ratios of medical costs.
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Objectives: To evaluate the cost efficiency of preventive treatment with OM 85 in 
patients with AR, asthma and COPD compared to the same patients the previous 
year only receiving standard of care. MethOds: This multi-centre, clinical trial was 
conducted in Argentina in 2010. Eighty-four patients with COPD, allergic rhinitis 
(AR) and asthma aged 16-65 years who had not received a bacterial lysate in 2009 
were included. In 2010, the same patients received OM-85 bacterial lysate capsule. 
Capsules were administered daily for 10 consecutive days per month for a duration 
of 3 consecutive months. Results: the number of reinfections and exacerbations 
in the OM 85 arm was decreased from 85% to 45.5% (p< 0.05) and from 65.7% to 
34.9% (p< 0.05) vs the previous year, respectively. Hospitalizations were 2% in the 
OM 85 group and 12% for the previous year. The average total cost per patient per 
month with AR caused by reinfections and exacerbations was 448.9 ARS and 269.9 
ARS in the OM 85 arm compared to 660.40 ARS and 574.40 ARS in the previous year. 
In patients with asthma total cost for reinfections and exacerbations was 487.9 ARS 
and 473.9 ARS in the OM 85 arm compared to 1’144 ARS and 970 ARS in the previ-
ous year. Reinfections and exacerbations total cost in COPD patients was 1356.5 
ARS and 1217.5 ARS in the OM 85 patients but amounted to 1’708.2 ARS and 1599.6 
ARS, respectively, in the previous year. cOnclusiOns: Preventive treatment with 
OM 85 in patients with allergic rhinitis, asthma and COPD significantly reduces 
reinfections rates, exacerbations and hospitalizations compared to the previous 
year. Associated cost savings have been substantial and ranged from 15% to 60% vs 
previous year (no prophylaxis).
